Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | GLS | O94925 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6868625 | 0.88 | MEN1 (0.63) | HSD17B10MEN1KMT2APLA2G2A | |
| SCHEMBL13485784 | 0.86 | HSD17B10 (0.69) | HSD17B10MEN1KMT2AGLSMAPK8 | |
| SCHEMBL4405092 | 0.84 | HSD17B10 (0.46) | HSD17B10MEN1KMT2AMAPK8MAPK9 | |
| SCHEMBL6500250 | 0.84 | HSD17B10 (0.67) | HSD17B10MEN1KMT2AGLSMAPK8 | |
| SCHEMBL4405083 | 0.84 | PLA2G2A (0.51) | HSD17B10MEN1KMT2AMAPK8MAPK9 | |
| SCHEMBL17993524 | 0.82 | HSD17B10 (0.60) | HSD17B10MEN1KMT2AGLSMAPK8 | |
| SCHEMBL1032357 | 0.82 | HSD17B10 (0.73) | HSD17B10MEN1KMT2AIDO1ADRA1A | |
| SCHEMBL30104106 | 0.82 | HSD17B10 (0.73) | HSD17B10MEN1KMT2AGLSIDO1 | |
| SCHEMBL4981706 | 0.82 | HSD17B10 (0.73) | HSD17B10MEN1KMT2AGLSIDO1 | |
| SCHEMBL19427715 | 0.82 | HSD17B10 (0.63) | HSD17B10MEN1KMT2AGLSMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937688-B1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | HSD17B10 1490/4885MEN1 4155/4885KMT2A 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.